Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

 Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Shots:

•      The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults
•     The collective results of the study demonstrated safety and efficacy of Lasmiditan, meeting all 1EP & 2EP, showing greater percentage of patients free of their most bothersome symptom (MBS)
•      Lasmiditan is a selective serotonin 5-HT1F agonist and is developed for acute treatment of migrane in adults

Click here to read full press release/ article | Ref: Eli Lilly | Image: Wall Street Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post